OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Jin Choi, Aaron N. Winn, M. Reza Skandari, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 10, pp. 1392-1400
Open Access | Times Cited: 52
Jin Choi, Aaron N. Winn, M. Reza Skandari, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 10, pp. 1392-1400
Open Access | Times Cited: 52
Showing 26-50 of 52 citing articles:
Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium
Sharif A. Sabe, Dwight D. Harris, Mark Broadwin, et al.
Vessel Plus (2024)
Open Access | Times Cited: 1
Sharif A. Sabe, Dwight D. Harris, Mark Broadwin, et al.
Vessel Plus (2024)
Open Access | Times Cited: 1
First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
Rui Deng, Kaibo Mei, Tiangang Song, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Rui Deng, Kaibo Mei, Tiangang Song, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
Joshua J. Neumiller, Wendy L. St. Peter, Jay H. Shubrook
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1367-1367
Open Access | Times Cited: 1
Joshua J. Neumiller, Wendy L. St. Peter, Jay H. Shubrook
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1367-1367
Open Access | Times Cited: 1
Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022
Jieqiong Zhang, Sen Xu, Xingyu Liu, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2752-2760
Closed Access | Times Cited: 1
Jieqiong Zhang, Sen Xu, Xingyu Liu, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2752-2760
Closed Access | Times Cited: 1
Care of Diabetes and the Sacrifice of Evidence-Based Medicine and Health Equity
David Goldberg
Journal of General Internal Medicine (2024) Vol. 39, Iss. 12, pp. 2333-2337
Closed Access | Times Cited: 1
David Goldberg
Journal of General Internal Medicine (2024) Vol. 39, Iss. 12, pp. 2333-2337
Closed Access | Times Cited: 1
Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023
Brady Wisniewski, Eric L. Smith, Jasmeen Kaur, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 30, Iss. 1, pp. 34-42
Open Access | Times Cited: 3
Brady Wisniewski, Eric L. Smith, Jasmeen Kaur, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 30, Iss. 1, pp. 34-42
Open Access | Times Cited: 3
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, et al.
Heart International (2023) Vol. 17, Iss. 2, pp. 12-12
Open Access | Times Cited: 2
Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, et al.
Heart International (2023) Vol. 17, Iss. 2, pp. 12-12
Open Access | Times Cited: 2
ВПРОВАДЖЕННЯ ЗАКОНУ УКРАЇНИ «ПРО ЛІКАРСЬКІ ЗАСОБИ» ЯК ФАКТОР РОЗВИТКУ ФАРМАЦЕВТИЧНОЇ ІНФОРМАТИКИ В НАЦІОНАЛЬНІЙ СИСТЕМІ ОХОРОНИ ЗДОРОВ’Я
А. І. Бойко
Фармацевтичний часопис (2023), Iss. 1, pp. 12-23
Open Access | Times Cited: 2
А. І. Бойко
Фармацевтичний часопис (2023), Iss. 1, pp. 12-23
Open Access | Times Cited: 2
Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation
Andrea Leonardo Cecchini, Federico Biscetti, Matteo Manzato, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16099-16099
Open Access | Times Cited: 2
Andrea Leonardo Cecchini, Federico Biscetti, Matteo Manzato, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16099-16099
Open Access | Times Cited: 2
Research progress on the role of extracellular vesicles in the pathogenesis of diabetic kidney disease
Jiangyuan Jin, Mianzhi Zhang
Renal Failure (2024) Vol. 46, Iss. 1
Open Access
Jiangyuan Jin, Mianzhi Zhang
Renal Failure (2024) Vol. 46, Iss. 1
Open Access
Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus
Chihiro Yoneda, Junji Kobayashi, Nobuichi Kuribayashi
Diabetology International (2024) Vol. 15, Iss. 3, pp. 569-576
Closed Access
Chihiro Yoneda, Junji Kobayashi, Nobuichi Kuribayashi
Diabetology International (2024) Vol. 15, Iss. 3, pp. 569-576
Closed Access
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
Noomi Vainer, Viktor Rotbain Curovic, Carsten Utoft Niemann, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 9, pp. 617-629
Open Access
Noomi Vainer, Viktor Rotbain Curovic, Carsten Utoft Niemann, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 9, pp. 617-629
Open Access
Assessing Variation in First-Line Type 2 Diabetes Treatment across eGFR Levels and Providers
Christina X. Ji, Saul Blecker, Michael Oberst, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Christina X. Ji, Saul Blecker, Michael Oberst, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Benchmarking the medication efficiency and technological progress of diabetes drugs
Hongwei Zhang, Chen Wang, Ting Xu, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access
Hongwei Zhang, Chen Wang, Ting Xu, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access
Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus—Clinical Practice Position Statement of the Polish Society of Nephrology
Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12941-12941
Open Access
Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12941-12941
Open Access
Prognostic models for heart failure in patients with type 2 diabetes: a systematic review and meta-analysis
Georgios Kostopoulos, Ioannis Doundoulakis, Konstantinos A. Toulis, et al.
Heart (2023) Vol. 109, Iss. 19, pp. 1436-1442
Closed Access | Times Cited: 1
Georgios Kostopoulos, Ioannis Doundoulakis, Konstantinos A. Toulis, et al.
Heart (2023) Vol. 109, Iss. 19, pp. 1436-1442
Closed Access | Times Cited: 1
First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Caroline Hanna, Kenneth Pettersen, Nathaniel Pedley
Annals of Internal Medicine (2023) Vol. 176, Iss. 4
Closed Access | Times Cited: 1
Caroline Hanna, Kenneth Pettersen, Nathaniel Pedley
Annals of Internal Medicine (2023) Vol. 176, Iss. 4
Closed Access | Times Cited: 1
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey
Alper Tuna Güven
PharmacoEconomics (2023) Vol. 41, Iss. 8, pp. 843-844
Closed Access | Times Cited: 1
Alper Tuna Güven
PharmacoEconomics (2023) Vol. 41, Iss. 8, pp. 843-844
Closed Access | Times Cited: 1
Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes
Ridhi Gudoor, Austen Suits, Jay H. Shubrook
Diabetology (2023) Vol. 4, Iss. 3, pp. 379-392
Open Access | Times Cited: 1
Ridhi Gudoor, Austen Suits, Jay H. Shubrook
Diabetology (2023) Vol. 4, Iss. 3, pp. 379-392
Open Access | Times Cited: 1
5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine
Shu Niu, Khalid A. Alkhuzam, Dawei Guan, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 463-472
Closed Access | Times Cited: 1
Shu Niu, Khalid A. Alkhuzam, Dawei Guan, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 463-472
Closed Access | Times Cited: 1
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease
Caressa Trueman, Emily H. Shin, Anthony Donovan, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 12, pp. 1275-1283
Open Access | Times Cited: 1
Caressa Trueman, Emily H. Shin, Anthony Donovan, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 12, pp. 1275-1283
Open Access | Times Cited: 1
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, et al.
Heart International (2023) Vol. 17, Iss. 2, pp. 12-12
Open Access | Times Cited: 1
Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, et al.
Heart International (2023) Vol. 17, Iss. 2, pp. 12-12
Open Access | Times Cited: 1
Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Lloyd W. Klein
The American Journal of Cardiology (2022) Vol. 187, pp. 74-75
Closed Access | Times Cited: 1
Lloyd W. Klein
The American Journal of Cardiology (2022) Vol. 187, pp. 74-75
Closed Access | Times Cited: 1
First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Sol Carriazo, Alberto Ortíz, Beatriz Fernández‐Fernández
Annals of Internal Medicine (2023) Vol. 176, Iss. 4
Closed Access
Sol Carriazo, Alberto Ortíz, Beatriz Fernández‐Fernández
Annals of Internal Medicine (2023) Vol. 176, Iss. 4
Closed Access
